<- Go Home
Longeveron Inc.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Market Cap
$29.1M
Volume
3.3M
Cash and Equivalents
$22.8M
EBITDA
-$16.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$1.4M
Profit Margin
73.00%
52 Week High
$23.90
52 Week Low
$0.77
Dividend
N/A
Price / Book Value
1.13
Price / Earnings
-0.46
Price / Tangible Book Value
1.25
Enterprise Value
$7.9M
Enterprise Value / EBITDA
-0.50
Operating Income
-$17.7M
Return on Equity
111.10%
Return on Assets
-53.14
Cash and Short Term Investments
$22.8M
Debt
$1.6M
Equity
$25.6M
Revenue
$1.9M
Unlevered FCF
-$9.4M
Sector
Biotechnology
Category
N/A